免疫检查点抑制剂相关肌肉骨骼表现的MRI研究:肌筋膜炎是突出影像学发现
这项前瞻性研究纳入130例接受免疫检查点抑制剂(ICI)治疗的患者,其中10例(7.7%)出现ICI诱导的肌肉骨骼免疫相关不良事件,中位发生时间为2.5个月。MRI显示多数患者存在肌炎和/或筋膜炎,且出现肌肉骨骼ir-AEs的患者肿瘤缓解率显著更高(50% vs 12.5%,P=0.0016)。
要点
- ICI相关肌肉骨骼ir-AEs发生率为7.7%,中位出现时间2.5个月。
- MRI显示肌筋膜炎为突出表现,肌肉/筋膜受累比滑膜更常见。
- 出现肌肉骨骼ir-AEs者肿瘤缓解率更高(50% vs 12.5%,P=0.0016)。
核心结论
- ICI诱导的肌肉骨骼表现发生率为7.7%,影像学上肌筋膜炎见于多数患者,提示肌肉/筋膜比滑膜更常受累。
- 症状总体为轻至中度,治疗反应良好,无需停用ICI。
研究设计与样本
- 前瞻性研究,纳入130例接受ICI治疗的患者,出现肌肉骨骼表现者转诊风湿科并完成受累区域MRI。
主要发现
- 10例(7.7%)发生ICI诱导的ir-AEs,从ICI治疗至症状出现的中位时间为2.5个月。
- 发现三种肌肉骨骼表现模式:突出关节受累(n=3)、突出关节周围受累(n=4,表现为手、足或膝弥漫肿胀)和肌筋膜炎(n=3)。
- 关节周围受累者MRI显示轻度滑膜炎,但周围组织肌炎和/或筋膜炎更突出;肌筋膜炎者临床表现为膝/大腿疼痛,MRI显示周围肌肉肌筋膜炎。
- 出现肌肉骨骼ir-AEs者肿瘤缓解率显著高于未出现者(50% vs 12.5%,P=0.0016)。
- 与Th1/Th2/Th17反应相关的细胞因子水平在有无肌肉骨骼ir-AEs的患者间相似。
关键数值与推荐
- 肌肉骨骼ir-AEs发生率7.7%(10/130)。
- 肿瘤缓解率比较:50% vs 12.5%,P=0.0016。
临床怎么用
- 对ICI治疗患者出现肌肉骨骼症状时应考虑ir-AEs,MRI有助于识别肌筋膜炎等突出影像学表现。
- 多数症状轻至中度且治疗反应良好,可无需停用ICI。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess: (i) the prevalence, and clinical and imaging characteristics of immune checkpoint inhibitor (ICI)-induced musculoskeletal immune-related adverse events (ir-AEs) in a prospective manner and (ii) whether serum levels of cytokines associated with the Th1/Th2/Th17 response are differentially expressed in patients with and without musculoskeletal Ir-AEs. METHODS: All patients treated with ICI who developed musculoskeletal manifestations were referred to the Rheumatology Department, and an MRI of the involved area(s) was performed. RESULTS: During the study period, a total of 130 patients were treated with ICIs. Of these, 10 (7.7%) developed ICI-induced Ir-AEs. The median time from ICI treatment since development of symptoms was 2.5 months. Three different patterns of musculoskeletal manifestations were found: (i) prominent joint involvement (n = 3); (ii) prominent 'periarticular' involvement (n = 4). These patients had diffuse swelling of the hands, feet or knees. MRI depicted mild synovitis with more prominent myositis and/or fasciitis in the surrounding tissues in all cases; (iii) myofasciitis (n = 3). Clinically, these patients presented with pain in the knee(s)/thigh(s), whereas MRI depicted myofasciitis of the surrounding muscles. Patients with musculoskeletal ir-AEs had significantly higher oncologic response rates compared with patients not exhibiting musculoskeletal ir-AEs (50% vs 12.5%, respectively, P = 0.0016). Cytokine levels associated with a Th1/Th2/Th17 response were similar between patients with and without musculoskeletal ir-AEs. Overall, symptoms were mild/moderate and responded well to treatment, with no need for ICI discontinuation. CONCLUSION: In our cohort, ICI-induced musculoskeletal manifestations developed in 7.7% of patients. Imaging evidence of myofasciitis was found in most patients, indicating that the muscle/fascia is more frequently involved than the synovium.
引用
- Daoussis D, Kraniotis P, Filippopoulou A, et al. An MRI study of immune checkpoint inhibitor-induced musculoskeletal manifestations myofasciitis is the prominent imaging finding. Rheumatology (Oxford). 2020. PMID: 32344435. doi:10.1093/rheumatology/kez361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。